Scientists are working on a COVID Vaccine that you can drink
What if you could drink your COVID-19 vaccine instead of rolling up your sleeve? No needle — just a “swish and swallow,” and your new immunity is down the hatch.
You might be able to within the next couple of years, as researchers expand their focus onto mucosal vaccines, which include nasal vaccines as well as “swish and swallow” oral vaccines such as QYNDR, which completed its phase 1 clinical trial and is currently waiting on more funding to conduct the more detailed, advanced trials that could actually bring the vaccine to market.
The QYNDR vaccine is pronounced “kinder,” because it’s a softer way to deliver a vaccine, says Kyle Flanigan, founder of QYNDR’s maker, US Specialty Formulations. Promising clinical trial results from New Zealand offer hope that QYNDR will be a viable option for protection against the string of COVID-19 variants circulating. The findings have not been peer-reviewed yet.
“It’s really challenging to have a vaccine survive making it through your digestive system,” Flanigan said. “We were able to figure out how to get a vaccine past the stomach and into the gut and have it be effective and induce the appropriate response.”But in order to advance it to the additional clinical trials needed to take it to review and market, they need funding from investors. This week, Flanigan was in San Francisco at the JP Morgan Healthcare Conference trying to get that funding.
When we talk about COVID-19 vaccines, we tend to talk about the same big names: Pfizer, Moderna, Johnson & Johnson, AstraZeneca. But around the world, researchers are nudging their way in with new names and new vaccine forms, like the nasal vaccines that have recently been rolled out in China and India.
As reported by Nature, researchers are still waiting on data to confirm whether mucosal vaccines “deliver” on their promise to stop infections. But if they outcompete on the infection front, they could be the new generation of COVID-19 vaccination. (SOURCE)